Introduction: Magnesium plays a role in a large number of cellular metabolic reactions.Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transportin the kidney.We designed this trial to investigate if Mg2+ serum level modifications may be relatedwith clinical response andoutcome in advancedcolorectal cancer patients during treatment withcetuximab plus irinotecan.Experimental Design: Sixty-eight heavily pretreatedmetastatic colorectal cancer patients wereevaluatedfor Mg2+ serum levels at the following time points: before; 6 hours; and1, 7, 14, 21, 50,and92 days after the start of treatment.Results: Basal Mg2+ median levels were significantly decreased just 7 days after the firstanticancer infusion and progressively decreased from the 7th day onward, reaching the highestsignificance at the last time point (P < 0.0001).Twenty-five patients showeda reduction in medianMg2+ circulating levels of at least 20% within the 3rdweek after the first infusion. Patients withthis reduction showed a response rate of 64.0% versus 25.6% in the nonreduced Mg2+ group.The median time to progression was 6.0 versus 3.6 months in the reduced Mg2+ group andin thatwithout reduction, respectively (P < 0.0001). Overall survival was longer in patients with Mg2+reduction than in those without (10.7 versus 8.9 months).Conclusions: Our results confirm that cetuximab treatment may induce a reduction of Mg2+circulating levels andoffer the first evidence that Mg2+ reduction may represent a new predictivefactor of efficacy in advanced colorectal cancer patients treated with cetuximab plus irinotecan
|Numero di pagine||6|
|Rivista||Clinical Cancer Research|
|Stato di pubblicazione||Published - 2008|
All Science Journal Classification (ASJC) codes
- Cancer Research
Russo, A., Fulfaro, F., Zobel, B. B., Silletta, M., Dicuonzo, G., Rocci, L., Galluzzo, S., Battistoni, F., Vincenzi, B., Adamo, V., Tonini, G., & Santini, D. (2008). Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clinical Cancer Research, 14, 4219-4224.